-+ 0.00%
-+ 0.00%
-+ 0.00%

Genmab Reports Q3 DARZALEX Net Sales Of $4.239B

Benzinga·10/13/2026 10:29:40
Listen to the news

Worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 4,239 million in the third quarter of 2026. Net trade sales were USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.